Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy

Inclusion Criteria:

• 1)6 years < age < 18 years old, regardless of gender; 2)Tumor patients diagnosed byhistopathology or bone marrow cytology; 3)Patients who have not been treated for the firsttime; 4)ECoG score ≤ 2; 5)The expected survival time is more than 8 months; 6)Thehematopoietic function of bone marrow was normal (ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,Hb ≥ 75 g / L, WBC ≥ 3.0 × 109 / L); 7)Receive high-intensity chemotherapy, such as scccglymphoma, CAV / ie, VIP regimen, etc., and expect bone marrow suppression of grade III orabove after chemotherapy.

8)Patient's parent or guardian signs informed consent.

Exclusion Criteria:

• Patients with any of the following items will not be enrolled in this study:

1. Local or systemic infection without adequate control;
2. Severe visceral dysfunction;
3. Liver function test: total bilirubin (TBIL), alanine aminotransferase (ALT),aspartate aminotransferase (AST) were all higher than 2.5 times of the upperlimit of normal value; if due to liver metastasis, the above indicators were morethan 5 times of the upper limit of normal value; renal function test: Serumcreatinine (CR) > 2 times of the upper limit of normal value;
4. Those who took the same kind of other tested drugs or accepted clinical trials ofother drugs within 4 weeks before enrollment;
5. Allergic to peg-rhG-CSF, rhG-CSF and other preparations or proteins expressed byEscherichia coli;
6. Serious mental illness, affecting informed consent and / or expression orobservation of adverse reactions;
7. The researcher judged the patients who were not suitable to participate.